Ependymoma Clinical Trial
Official title:
Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, Central Nervous System (CNS)- Primitive Neuroectodermal Tumour (PNET), or Ependymoma
The Register is based on the study HIT 2000 that recruited patients until 31.12.2011. All
german patients with intracranial medulloblastoma, CNS-PNET, ependymoma can be included in
the register. Object of the register is to maintain the quality of diagnostic standard by
using of central review (Neuroradiology, Pathology, and cranio spinal fluid (CSF) cytology).
Furthermore, the register should enable to continue the collection of epidemiologic data and
biological material (tumor material, CSF, and blood) for associated studies.
The Register is based on the study HIT 2000 that recruited patients until 31.12.2011. All
german patients with intracranial medulloblastoma, CNS-PNET, ependymoma can be included in
the register. Object of the register is to maintain the quality of diagnostic standard by
using of central review (Neuroradiology, Pathology, and cranio spinal fluid (CSF) cytology).
Furthermore, the register should enable to continue the collection of epidemiologic data and
biological material (tumor material, CSF, and blood) for associated studies.
The register gives recommendations for the therapy of the patients, but these are not
mandatory.
;
Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00994071 -
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
|
Phase 1 | |
| Completed |
NCT01171469 -
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
|
Phase 1 | |
| Completed |
NCT00520936 -
A Study of Pemetrexed in Children With Recurrent Cancer
|
Phase 2 | |
| Recruiting |
NCT04541082 -
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
|
Phase 1 | |
| Completed |
NCT02502708 -
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
|
Phase 1 | |
| Recruiting |
NCT04049669 -
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
|
Phase 2 | |
| Recruiting |
NCT06038760 -
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
|
||
| Active, not recruiting |
NCT03220035 -
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
| Completed |
NCT03043391 -
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
|
Phase 1 | |
| Completed |
NCT03194906 -
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
|
Phase 2 | |
| Suspended |
NCT03095248 -
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT02125786 -
A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma
|
Phase 2 | |
| Active, not recruiting |
NCT01096368 -
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
|
Phase 3 | |
| Terminated |
NCT01247922 -
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
|
Phase 2 | |
| Completed |
NCT03900689 -
Social Determinants of Health in Glioblastoma Population
|
||
| Recruiting |
NCT04661384 -
Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma
|
Phase 1 | |
| Completed |
NCT03434262 -
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
|
Phase 1 | |
| Recruiting |
NCT05259605 -
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
|
||
| Terminated |
NCT01836549 -
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT03638167 -
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
|
Phase 1 |